J Korean Assoc Oral Maxillofac Surg.  2015 Aug;41(4):171-175. 10.5125/jkaoms.2015.41.4.171.

Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis

• Kaur J
• Jacobs R

• KMID: 2364012
• DOI: http://doi.org/10.5125/jkaoms.2015.41.4.171

Abstract

OBJECTIVES
The objective of this study was to identify salivary and serum concentrations of interleukin (IL)-8, IL-6, and tumor necrosis factor alpha (TNF-alpha) in patients with oral lichen planus, oral leukoplakia, oral submucous fibrosis, and healthy controls.
MATERIALS AND METHODS
Patients selected included 54 oral lichen planus (41 to 65 years), 50 oral leukoplakia (42 to 65 years), 51 oral submucous fibrosis (41 to 65 years), and 50 healthy controls (42 to 65 years). Oral lichen planus, oral leukoplakia, and oral submucous fibrosis cases were diagnosed using histopathological analysis. Salivary and serum cytokine concentrations were measured using enzyme-linked immunoassay kits in all subjects.
RESULTS
The levels of serum and salivary TNF-alpha, IL-6, and IL-8 were statistically significantly increased in oral leukoplakia, submucous fibrosis, and lichen planus in contrast to normal healthy subjects (P<0.05). Serum and salivary correlation analysis revealed strong and highly significant correlations for TNF-alpha, IL-6, and IL-8 in all groups (r=0.72-0.82, P<0.05).
CONCLUSION
Salivary and serum cytokines were also elevated when analyzed in oral precancerous lesions. Thus, salivary and serum IL-8, IL-6, and TNF-alpha levels might act as diagnostic markers for detection of oral precancer.

Keyword

Saliva; Oral lichen planus; Oral leukoplakia; Oral submucous fibrosis; Cytokines

MeSH Terms

Cytokines
Fibrosis
Humans
Immunoassay
Interleukin-6
Interleukin-8
Interleukins
Leukoplakia, Oral*
Lichen Planus
Lichen Planus, Oral*
Oral Submucous Fibrosis*
Saliva
Tumor Necrosis Factor-alpha
Cytokines
Interleukin-6
Interleukin-8
Interleukins
Tumor Necrosis Factor-alpha

Reference

1. Petersen PE. The world oral health report 2003. Geneva: World Health Organization;2003.

2. Petersen PE. The World Oral Health Report 2003: continuous improvement of oral health in the 21st century--the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol. 2003; 31(Suppl 1):3–23. PMID: 15015736.

3. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med. 2001; 344:1323–1326. PMID: 11320393.

4. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003; 14:47–62. PMID: 12764019.

5. Gupta PC, Bhonsle RB, Murti PR, Daftary DK, Mehta FS, Pindborg JJ. An epidemiologic assessment of cancer risk in oral precancerous lesions in India with special reference to nodular leukoplakia. Cancer. 1989; 63:2247–2252. PMID: 2720574.

6. Geum DH, Roh YC, Yoon SY, Kim HG, Lee JH, Song JM, et al. The impact factors on 5-year survival rate in patients operated with oral cancer. J Korean Assoc Oral Maxillofac Surg. 2013; 39:207–216. PMID: 24471047.

7. Rai B, Kaur J, Jacobs R. Direct tissue fluorescence imaging in relation to tissue, serum and salivary protoporphyrin for oral precancerous and cancerous lesions. Oral Oncol. 2011; 47(Suppl 1):S40.

8. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996; 274:784–787. PMID: 8864119.

9. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009; 45:317–323. PMID: 18674954.

10. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature. 2004; 431:461–466. PMID: 15329734.

11. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004; 6:203–208. PMID: 15380510.

12. Shishodia S, Aggarwal BB. Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res. 2004; 119:139–173. PMID: 15164877.

13. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005; 29:42–45. PMID: 15734216.

14. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23:363–398. PMID: 12680238.

15. Piva MR, DE Souza LB, Martins-Filho PR, Nonaka CF, DE Santana Santos T, DE Souza Andrade ES, et al. Role of inflammation in oral carcinogenesis (part II): CD8, FOXP3, TNF-α, TGF-β and NF-κB expression. Oncol Lett. 2013; 5:1909–1914. PMID: 23833665.

16. Chang KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013; 148:786–791. PMID: 23426713.

17. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999; 5:1369–1379. PMID: 10389921.

18. Cohen RF, Contrino J, Spiro JD, Mann EA, Chen LL, Kreutzer DL. Interleukin-8 expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1995; 121:202–209. PMID: 7840929.

19. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNFalpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005; 44:77–82. PMID: 16075467.

20. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130:929–935. PMID: 15313862.

21. Brailo V, Vucićević-Boras V, Cekić-Arambasin A, Alajbeg IZ, Milenović A, Lukac J. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2006; 42:370–373. PMID: 16324876.

22. Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol. 2008; 79:1913–1919. PMID: 18834246.

23. Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine. 1996; 8:578–585. PMID: 8891439.

24. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005; 41:2502–2512. PMID: 16199153.

25. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci. 2010; 52:251–256. PMID: 20587949.

26. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860–867. PMID: 12490959.

27. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002; 87:264–267. PMID: 12177792.